254 related articles for article (PubMed ID: 32276394)
21. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
[TBL] [Abstract][Full Text] [Related]
22. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
[TBL] [Abstract][Full Text] [Related]
23. Indoxyl sulfate is a nephro-vascular toxin.
Niwa T
J Ren Nutr; 2010 Sep; 20(5 Suppl):S2-6. PubMed ID: 20797565
[TBL] [Abstract][Full Text] [Related]
24. Neointimal hyperplasia in the inferior vena cava of adenine-induced chronic kidney disease rats with aortocaval fistulas.
Du J; Liang L; Liu S; Yang X; Cao S; Zhang H; Su H; Gong X; Chen Q; Kong X; Xu D
Clin Exp Nephrol; 2020 Nov; 24(11):1007-1014. PubMed ID: 32666345
[TBL] [Abstract][Full Text] [Related]
25. Review of the efficacy of AST-120 (KREMEZIN
Asai M; Kumakura S; Kikuchi M
Ren Fail; 2019 Nov; 41(1):47-56. PubMed ID: 30732506
[TBL] [Abstract][Full Text] [Related]
26. Increased expression of HIF-1alpha, VEGF-A and its receptors, MMP-2, TIMP-1, and ADAMTS-1 at the venous stenosis of arteriovenous fistula in a mouse model with renal insufficiency.
Misra S; Shergill U; Yang B; Janardhanan R; Misra KD
J Vasc Interv Radiol; 2010 Aug; 21(8):1255-61. PubMed ID: 20598569
[TBL] [Abstract][Full Text] [Related]
27. Uremic Toxic Blood-Brain Barrier Disruption Mediated by AhR Activation Leads to Cognitive Impairment during Experimental Renal Dysfunction.
Bobot M; Thomas L; Moyon A; Fernandez S; McKay N; Balasse L; Garrigue P; Brige P; Chopinet S; Poitevin S; Cérini C; Brunet P; Dignat-George F; Burtey S; Guillet B; Hache G
J Am Soc Nephrol; 2020 Jul; 31(7):1509-1521. PubMed ID: 32527975
[TBL] [Abstract][Full Text] [Related]
28. PDGFRA in vascular adventitial MSCs promotes neointima formation in arteriovenous fistula in chronic kidney disease.
Song K; Qing Y; Guo Q; Peden EK; Chen C; Mitch WE; Truong L; Cheng J
JCI Insight; 2020 Nov; 5(21):. PubMed ID: 33001865
[TBL] [Abstract][Full Text] [Related]
29. Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients.
Yamamoto S; Kazama JJ; Omori K; Matsuo K; Takahashi Y; Kawamura K; Matsuto T; Watanabe H; Maruyama T; Narita I
Sci Rep; 2015 Sep; 5():14381. PubMed ID: 26395517
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Different Types of Oral Adsorbent Therapy in Patients with Chronic Kidney Disease: A Multicenter, Randomized, Phase IV Clinical Trial.
Kee YK; Han SY; Kang DH; Noh JW; Jeong KH; Kim GH; Kim YW; Kim BS
Yonsei Med J; 2021 Jan; 62(1):41-49. PubMed ID: 33381933
[TBL] [Abstract][Full Text] [Related]
31. Effects of oral adsorbent on gene expression profile in uremic rat kidney: cDNA array analysis.
Aoyama I; Enomoto A; Niwa T
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S8-14. PubMed ID: 12612943
[TBL] [Abstract][Full Text] [Related]
32. Administration of oral charcoal adsorbent (AST-120) suppresses low-turnover bone progression in uraemic rats.
Iwasaki Y; Yamato H; Nii-Kono T; Fujieda A; Uchida M; Hosokawa A; Motojima M; Fukagawa M
Nephrol Dial Transplant; 2006 Oct; 21(10):2768-74. PubMed ID: 16820376
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-9 mediates chronic kidney disease-dependent vein graft disease: a role for mast cells.
Zhang L; Wu JH; Otto JC; Gurley SB; Hauser ER; Shenoy SK; Nagi K; Brian L; Wertman V; Mattocks N; Lawson JH; Freedman NJ
Cardiovasc Res; 2017 Nov; 113(13):1551-1559. PubMed ID: 29048463
[TBL] [Abstract][Full Text] [Related]
34. Reduction of indoxyl sulfate by AST-120 attenuates monocyte inflammation related to chronic kidney disease.
Ito S; Higuchi Y; Yagi Y; Nishijima F; Yamato H; Ishii H; Osaka M; Yoshida M
J Leukoc Biol; 2013 Jun; 93(6):837-45. PubMed ID: 23362306
[TBL] [Abstract][Full Text] [Related]
35. AST-120 ameliorates lowered exercise capacity and mitochondrial biogenesis in the skeletal muscle from mice with chronic kidney disease via reducing oxidative stress.
Nishikawa M; Ishimori N; Takada S; Saito A; Kadoguchi T; Furihata T; Fukushima A; Matsushima S; Yokota T; Kinugawa S; Tsutsui H
Nephrol Dial Transplant; 2015 Jun; 30(6):934-42. PubMed ID: 25878055
[TBL] [Abstract][Full Text] [Related]
36. An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure.
Shimoishi K; Anraku M; Kitamura K; Tasaki Y; Taguchi K; Hashimoto M; Fukunaga E; Maruyama T; Otagiri M
Pharm Res; 2007 Jul; 24(7):1283-9. PubMed ID: 17387602
[TBL] [Abstract][Full Text] [Related]
37. Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?
Yamaguchi J; Tanaka T; Inagi R
Nephron; 2017; 135(3):201-206. PubMed ID: 27960172
[TBL] [Abstract][Full Text] [Related]
38. Notch signaling in bone marrow-derived FSP-1 cells initiates neointima formation in arteriovenous fistulas.
Liang M; Guo Q; Huang F; Han G; Song K; Luo J; Cheng H; Hu H; Peden EK; Chen C; Mitch WE; Du J; Fu X; Truong L; Cheng J
Kidney Int; 2019 Jun; 95(6):1347-1358. PubMed ID: 30799025
[TBL] [Abstract][Full Text] [Related]
39. Effect of uremic toxin-indoxyl sulfate on the skeletal system.
Liu WC; Wu CC; Lim PS; Chien SW; Hou YC; Zheng CM; Shyu JF; Lin YF; Lu KC
Clin Chim Acta; 2018 Sep; 484():197-206. PubMed ID: 29864403
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Bennis Y; Cluet Y; Titeca-Beauport D; El Esper N; Ureña P; Bodeau S; Combe C; Dussol B; Fouque D; Choukroun G; Liabeuf S
Toxins (Basel); 2019 May; 11(5):. PubMed ID: 31109001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
